Trial Profile
Prospective, multicenter,randomized,double blind, two arm, parallel group, active control, comparative clinical study to evaluate efficacy and safety of R-TPR-045/Prolia in postmenopausal women with osteoporosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Dec 2020
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Reliance Life Sciences
- 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Nov 2018 New trial record